Isolated Atrioventricular Block in the Fetus A Retrospective, Multinational, Multicenter Study of 175 Patients

被引:163
作者
Eliasson, Hakan [1 ]
Sonesson, Sven-Erik
Sharland, Gurleen
Granath, Fredrik [2 ,3 ]
Simpson, John M.
Carvalho, Julene S.
Jicinska, Hana
Tomek, Viktor
Dangel, Joanna
Zielinsky, Paulo
Respondek-Liberska, Maria
Freund, Matthias W.
Mellander, Mats
Bartrons, Joaquim
Gardiner, Helena M.
机构
[1] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Cardiol Q1 03, S-17176 Stockholm, Sweden
[2] Karolinska Univ Hosp, Clin Epidemiol Unit, S-17176 Stockholm, Sweden
[3] Karolinska Inst, Stockholm, Sweden
关键词
atrioventricular block; fetal heart; lupus erythematosus; systemic; therapeutics; FETAL TREATMENT IMPROVES; HEART-BLOCK; STEROID-THERAPY; INFANTS BORN; ABNORMALITIES; CHILDHOOD; DIAGNOSIS; MOTHERS;
D O I
10.1161/CIRCULATIONAHA.111.041970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Isolated complete atrioventricular block in the fetus is a rare but potentially lethal condition in which the effect of steroid treatment on outcome is unclear. The objective of this work was to study risk factors associated with death and the influence of steroid treatment on outcome. Methods and Results-We studied 175 fetuses diagnosed with second-or third-degree atrioventricular block (2000-2007) retrospectively in a multinational, multicenter setting. In 80% of 162 pregnancies with documented antibody status, atrioventricular block was associated with maternal anti-Ro/SSA antibodies. Sixty-seven cases (38%) were treated with fluorinated corticosteroids for a median of 10 weeks (1-21 weeks). Ninety-one percent were alive at birth, and survival in the neonatal period was 93%, similar in steroid-treated and untreated fetuses, regardless of degree of block and/or presence of anti-Ro/SSA. Variables associated with death were gestational age <20 weeks, ventricular rate <= 50 bpm, fetal hydrops, and impaired left ventricular function at diagnosis. The presence of >= 1 of these variables was associated with a 10-fold increase in mortality before birth and a 6-fold increase in the neonatal period independently of treatment. Except for a lower gestational age at diagnosis in treated than untreated (23.4 +/- 2.9 versus 24.9 +/- 4.9 weeks; P = 0.02), risk factors were distributed equally between treatment groups. Two-thirds of survivors had a pacemaker by 1 year of age; 8 children developed cardiomyopathy. Conclusions-Risk factors associated with a poor outcome were gestation <20 weeks, ventricular rate <= 50 bpm, hydrops, and impaired left ventricular function. No significant effect of treatment with fluorinated corticosteroids was seen. (Circulation. 2011; 124: 1919-1926.)
引用
收藏
页码:1919 / 1926
页数:8
相关论文
共 21 条
[1]   Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies [J].
Askanase, AD ;
Friedman, DM ;
Copel, J ;
Dische, MR ;
Dubin, A ;
Starc, TJ ;
Katholi, MC ;
Buyon, JP .
LUPUS, 2002, 11 (03) :145-151
[2]   Atrioventricular block detected in fetal life: associated anomalies and potential prognostic markers [J].
Berg, C ;
Geipel, A ;
Kohl, T ;
Breuer, J ;
Germer, U ;
Krapp, M ;
Baschat, AA ;
Hansmann, M ;
Gembruch, U .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2005, 26 (01) :4-15
[3]   Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature [J].
Breur, JMPJ ;
Visser, GHA ;
Kruize, AA ;
Stoutenbeek, P ;
Meijboom, EJ .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2004, 24 (04) :467-472
[4]   SUCCESSFUL IN-UTERO THERAPY OF FETAL HEART-BLOCK [J].
COPEL, JA ;
BUYON, JP ;
KLEINMAN, CS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (05) :1384-1390
[5]   Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block [J].
Costedoat-Chalumeau, N ;
Amoura, Z ;
Hong, DLT ;
Wechsler, B ;
Vauthier, D ;
Ghillani, P ;
Papo, T ;
Fain, O ;
Musset, L ;
Piette, JC .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (10) :1010-1012
[6]   Atrial and ventricular rate response and patterns of heart rate acceleration during maternal-fetal terbutaline treatment of fetal complete heart block [J].
Cuneo, Bettina F. ;
Zhao, Hui ;
Strasburger, Janette F. ;
Ovadia, Marc ;
Huhta, James C. ;
Wakai, Ronald T. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (04) :661-665
[7]   Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases - a multicentre prospective study [J].
Gerosa, M. ;
Cimaz, R. ;
Stramba-Badiale, M. ;
Goulene, K. ;
Meregalli, E. ;
Trespidi, L. ;
Acaia, B. ;
Cattaneo, R. ;
Tincani, A. ;
Motta, M. ;
Doria, A. ;
Zuliang, F. ;
Milanesi, O. ;
Brucato, A. ;
Riboldi, P. ;
Meroni, P. L. .
RHEUMATOLOGY, 2007, 46 (08) :1285-1289
[8]   THERAPEUTIC TRIAL OF SYMPATHOMIMETICS IN 3 CASES OF COMPLETE HEART-BLOCK IN THE FETUS [J].
GROVES, AMM ;
ALLAN, LD ;
ROSENTHAL, E .
CIRCULATION, 1995, 92 (12) :3394-3396
[9]  
Ismail K M, 2001, J Matern Fetal Med, V10, P175
[10]  
Jaeggi ET, 2004, CIRCULATION, V110, P1542, DOI 10.1161/01.CIR.0000142046.58632.3A